Ocugen (OCGN) Cash from Financing Activities (2014 - 2026)
Ocugen (OCGN) posted Cash from Financing Activities of $35.0 million for Q1 2026, up 1749100.0% on a QoQ basis from $2000.0 in Q4 2025, and up 2909.96% year-over-year from $1.2 million in Q1 2025.
Ocugen (OCGN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Ocugen's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $35.0 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 2909.96% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (down 16.0% YoY) and the FY2025 annual result came in at $17.3 million, down 73.28% from the prior year.
- Cash from Financing Activities was $35.0 million for Q1 2026 at Ocugen, up from $2000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $50.1 million in Q1 2022 and bottomed at -$1.2 million in Q1 2025.
- A 5-year average of $11.6 million and a median of $962000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 188475.0% — and 2025, when it plunged 758.62%.
- Ocugen's Cash from Financing Activities stood at $8.2 million in 2022, then tumbled by 99.8% to $16000.0 in 2023, then jumped by 188475.0% to $30.2 million in 2024, then tumbled by 99.99% to $2000.0 in 2025, then soared by 1749100.0% to $35.0 million in 2026.
- Business Quant data shows OCGN's Cash from Financing Activities at $35.0 million in Q1 2026, $2000.0 in Q4 2025, and $18.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | 34.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.98 Mn |
| Mar 31, 2026 | 34.98 Mn |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 18.51 Mn |
| Sep 30, 2025 | 18.51 Mn |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Jun 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 45,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |